Cargando…

HPV Carcinomas in Immunocompromised Patients

Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide and can result in pre-malignancies or overt malignancies of the skin and mucosal surfaces. HPV-related illnesses are an important personal and public health problem causing physical, mental, sexual and fin...

Descripción completa

Detalles Bibliográficos
Autores principales: Reusser, Nicole M., Downing, Christopher, Guidry, Jacqueline, Tyring, Stephen K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470124/
https://www.ncbi.nlm.nih.gov/pubmed/26239127
http://dx.doi.org/10.3390/jcm4020260
_version_ 1782376713309650944
author Reusser, Nicole M.
Downing, Christopher
Guidry, Jacqueline
Tyring, Stephen K.
author_facet Reusser, Nicole M.
Downing, Christopher
Guidry, Jacqueline
Tyring, Stephen K.
author_sort Reusser, Nicole M.
collection PubMed
description Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide and can result in pre-malignancies or overt malignancies of the skin and mucosal surfaces. HPV-related illnesses are an important personal and public health problem causing physical, mental, sexual and financial detriments. Moreover, this set of malignancies severely affects the immunosuppressed population, particularly HIV-positive patients and organ-transplant recipients. There is growing incidence of HPV-associated anogenital malignancies as well as a decrease in the average age of affected patients, likely related to the rising number of high-risk individuals. Squamous cell carcinoma is the most common type of HPV-related malignancy. Current treatment options for HPV infection and subsequent disease manifestations include imiquimod, retinoids, intralesional bleomycin, and cidofovir; however, primary prevention with HPV vaccination remains the most effective strategy. This review will discuss anogenital lesions in immunocompromised patients, cutaneous warts at nongenital sites, the association of HPV with skin cancer in immunocompromised patients, warts and carcinomas in organ-transplant patients, HIV-positive patients with HPV infections, and the management of cutaneous disease in the immunocompromised patient.
format Online
Article
Text
id pubmed-4470124
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-44701242015-07-28 HPV Carcinomas in Immunocompromised Patients Reusser, Nicole M. Downing, Christopher Guidry, Jacqueline Tyring, Stephen K. J Clin Med Review Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide and can result in pre-malignancies or overt malignancies of the skin and mucosal surfaces. HPV-related illnesses are an important personal and public health problem causing physical, mental, sexual and financial detriments. Moreover, this set of malignancies severely affects the immunosuppressed population, particularly HIV-positive patients and organ-transplant recipients. There is growing incidence of HPV-associated anogenital malignancies as well as a decrease in the average age of affected patients, likely related to the rising number of high-risk individuals. Squamous cell carcinoma is the most common type of HPV-related malignancy. Current treatment options for HPV infection and subsequent disease manifestations include imiquimod, retinoids, intralesional bleomycin, and cidofovir; however, primary prevention with HPV vaccination remains the most effective strategy. This review will discuss anogenital lesions in immunocompromised patients, cutaneous warts at nongenital sites, the association of HPV with skin cancer in immunocompromised patients, warts and carcinomas in organ-transplant patients, HIV-positive patients with HPV infections, and the management of cutaneous disease in the immunocompromised patient. MDPI 2015-01-29 /pmc/articles/PMC4470124/ /pubmed/26239127 http://dx.doi.org/10.3390/jcm4020260 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Reusser, Nicole M.
Downing, Christopher
Guidry, Jacqueline
Tyring, Stephen K.
HPV Carcinomas in Immunocompromised Patients
title HPV Carcinomas in Immunocompromised Patients
title_full HPV Carcinomas in Immunocompromised Patients
title_fullStr HPV Carcinomas in Immunocompromised Patients
title_full_unstemmed HPV Carcinomas in Immunocompromised Patients
title_short HPV Carcinomas in Immunocompromised Patients
title_sort hpv carcinomas in immunocompromised patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470124/
https://www.ncbi.nlm.nih.gov/pubmed/26239127
http://dx.doi.org/10.3390/jcm4020260
work_keys_str_mv AT reussernicolem hpvcarcinomasinimmunocompromisedpatients
AT downingchristopher hpvcarcinomasinimmunocompromisedpatients
AT guidryjacqueline hpvcarcinomasinimmunocompromisedpatients
AT tyringstephenk hpvcarcinomasinimmunocompromisedpatients